Zulli AL - Search Results

1

Optimization of the beta-aminoester class of factor Xa inhibitors. Part 1: P(4) and side-chain modifications for improved in vitro potency.

Czekaj M, Klein SI, Guertin KR, Gardner CJ, Zulli AL, Pauls HW, Spada AP, Cheney DL, Brown KD, Colussi DJ, Chu V, Leadley RJ, Dunwiddie CT. Czekaj M, et al. Among authors: zulli al. Bioorg Med Chem Lett. 2002 Jun 17;12(12):1667-70. doi: 10.1016/s0960-894x(02)00212-3. Bioorg Med Chem Lett. 2002. PMID: 12039586

2

Optimization of the beta-aminoester class of factor Xa inhibitors. Part 2: Identification of FXV673 as a potent and selective inhibitor with excellent In vivo anticoagulant activity.

Guertin KR, Gardner CJ, Klein SI, Zulli AL, Czekaj M, Gong Y, Spada AP, Cheney DL, Maignan S, Guilloteau JP, Brown KD, Colussi DJ, Chu V, Heran CL, Morgan SR, Bentley RG, Dunwiddie CT, Leadley RJ, Pauls HW. Guertin KR, et al. Among authors: zulli al. Bioorg Med Chem Lett. 2002 Jun 17;12(12):1671-4. doi: 10.1016/s0960-894x(02)00213-5. Bioorg Med Chem Lett. 2002. PMID: 12039587

3

Pharmacological characterization of a novel factor Xa inhibitor, FXV673.

Chu V, Brown K, Colussi D, Gao J, Bostwick J, Kasiewski C, Bentley R, Morgan S, Guertin K, Pauls HW, Gong Y, Zulli A, Perrone MH, Dunwiddie CT, Leadley RJ. Chu V, et al. Thromb Res. 2001 Aug 15;103(4):309-24. doi: 10.1016/s0049-3848(01)00328-0. Thromb Res. 2001. PMID: 11562341

4

Potent quinoxaline-based inhibitors of PDGF receptor tyrosine kinase activity. Part 1: SAR exploration and effective bioisosteric replacement of a phenyl substituent.

Myers MR, He W, Hanney B, Setzer N, Maguire MP, Zulli A, Bilder G, Galzcinski H, Amin D, Needle S, Spada AP. Myers MR, et al. Bioorg Med Chem Lett. 2003 Sep 15;13(18):3091-5. doi: 10.1016/s0960-894x(03)00654-1. Bioorg Med Chem Lett. 2003. PMID: 12941341

5

Design and synthesis of dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole oximes as potent dual inhibitors of TIE-2 and VEGF-R2 receptor tyrosine kinases.

Dandu R, Zulli AL, Bacon ER, Underiner T, Robinson C, Chang H, Miknyoczki S, Grobelny J, Ruggeri BA, Yang S, Albom MS, Angeles TS, Aimone LD, Hudkins RL. Dandu R, et al. Among authors: zulli al. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1916-21. doi: 10.1016/j.bmcl.2008.02.001. Epub 2008 Feb 7. Bioorg Med Chem Lett. 2008. PMID: 18308565

6

Novel C-3 N-urea, amide, and carbamate dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole analogs as potent TIE-2 and VEGF-R2 dual inhibitors.

Becknell NC, Zulli AL, Angeles TS, Yang S, Albom MS, Aimone LD, Robinson C, Chang H, Hudkins RL. Becknell NC, et al. Among authors: zulli al. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5368-72. doi: 10.1016/j.bmcl.2006.07.066. Epub 2006 Aug 4. Bioorg Med Chem Lett. 2006. PMID: 16890434

7

8-THP-DHI analogs as potent Type I dual TIE-2/VEGF-R2 receptor tyrosine kinase inhibitors.

Hudkins RL, Zulli AL, Underiner TL, Angeles TS, Aimone LD, Meyer SL, Pauletti D, Chang H, Fedorov EV, Almo SC, Fedorov AA, Ruggeri BA. Hudkins RL, et al. Among authors: zulli al. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3356-60. doi: 10.1016/j.bmcl.2010.04.021. Epub 2010 Apr 13. Bioorg Med Chem Lett. 2010. PMID: 20430619

8

TIE-2/VEGF-R2 SAR and in vitro activity of C3-acyl dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole analogs.

Underiner TL, Ruggeri B, Aimone L, Albom M, Angeles T, Chang H, Hudkins RL, Hunter K, Josef K, Robinson C, Weinberg L, Yang S, Zulli A. Underiner TL, et al. Bioorg Med Chem Lett. 2008 Apr 1;18(7):2368-72. doi: 10.1016/j.bmcl.2008.02.069. Epub 2008 Mar 4. Bioorg Med Chem Lett. 2008. PMID: 18343109

9

Identification of pyridazin-3-one derivatives as potent, selective histamine H₃ receptor inverse agonists with robust wake activity.

Hudkins RL, Aimone LD, Bailey TR, Bendesky RJ, Dandu RR, Dunn D, Gruner JA, Josef KA, Lin YG, Lyons J, Marcy VR, Mathiasen JR, Sundar BG, Tao M, Zulli AL, Raddatz R, Bacon ER. Hudkins RL, et al. Among authors: zulli al. Bioorg Med Chem Lett. 2011 Sep 15;21(18):5493-7. doi: 10.1016/j.bmcl.2011.06.108. Epub 2011 Jun 30. Bioorg Med Chem Lett. 2011. PMID: 21782432

10

Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): An Orally Bioavailable β-Lactamase Inhibitor for Enterobacterales Expressing Ambler Class A, C, and D Enzymes.

Trout RE, Zulli A, Mesaros E, Jackson RW, Boyd S, Liu B, Hamrick J, Daigle D, Chatwin CL, John K, McLaughlin L, Cusick SM, Weiss WJ, Pulse ME, Pevear DC, Moeck G, Xerri L, Burns CJ. Trout RE, et al. J Med Chem. 2021 Jul 22;64(14):10155-10166. doi: 10.1021/acs.jmedchem.1c00437. Epub 2021 Jun 30. J Med Chem. 2021. PMID: 34191513 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

17 results

Search Page

Filters